Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.
dc.contributor.author | Freel, SA | |
dc.contributor.author | Picking, RA | |
dc.contributor.author | Ferrari, G | |
dc.contributor.author | Ding, H | |
dc.contributor.author | Ochsenbauer, C | |
dc.contributor.author | Kappes, JC | |
dc.contributor.author | Kirchherr, J | |
dc.contributor.author | Soderberg, K | |
dc.contributor.author | Weinhold, KJ | |
dc.contributor.author | Cunningham, CK | |
dc.contributor.author | Denny, T | |
dc.contributor.author | Crump, JA | |
dc.contributor.author | Cohen, MS | |
dc.contributor.author | McMichael, AJ | |
dc.contributor.author | Haynes, BF | |
dc.contributor.author | Tomaras, GD | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2017-03-02T19:18:41Z | |
dc.date.available | 2017-03-02T19:18:41Z | |
dc.date.issued | 2012-06 | |
dc.description.abstract | CD8-mediated virus inhibition can be detected in HIV-1-positive subjects who naturally control virus replication. Characterizing the inhibitory function of CD8(+) T cells during acute HIV-1 infection (AHI) can elucidate the nature of the CD8(+) responses that can be rapidly elicited and that contribute to virus control. We examined the timing and HIV-1 antigen specificity of antiviral CD8(+) T cells during AHI. Autologous and heterologous CD8(+) T cell antiviral functions were assessed longitudinally during AHI in five donors from the CHAVI 001 cohort using a CD8(+) T cell-mediated virus inhibition assay (CD8 VIA) and transmitted/founder (T/F) viruses. Potent CD8(+) antiviral responses against heterologous T/F viruses appeared during AHI at the first time point sampled in each of the 5 donors (Fiebig stages 1/2 to 5). Inhibition of an autologous T/F virus was durable to 48 weeks; however, inhibition of heterologous responses declined concurrent with the resolution of viremia. HIV-1 viruses from 6 months postinfection were more resistant to CD8(+)-mediated virus inhibition than cognate T/F viruses, demonstrating that the virus escapes early from CD8(+) T cell-mediated inhibition of virus replication. CD8(+) T cell antigen-specific subsets mediated inhibition of T/F virus replication via soluble components, and these soluble responses were stimulated by peptide pools that include epitopes that were shown to drive HIV-1 escape during AHI. These data provide insights into the mechanisms of CD8-mediated virus inhibition and suggest that functional analyses will be important for determining whether similar antigen-specific virus inhibition can be induced by T cell-directed vaccine strategies. | |
dc.identifier | ||
dc.identifier | JVI.00437-12 | |
dc.identifier.eissn | 1098-5514 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | American Society for Microbiology | |
dc.relation.ispartof | J Virol | |
dc.relation.isversionof | 10.1128/JVI.00437-12 | |
dc.subject | Adult | |
dc.subject | CD8-Positive T-Lymphocytes | |
dc.subject | Cells, Cultured | |
dc.subject | Cohort Studies | |
dc.subject | Down-Regulation | |
dc.subject | Female | |
dc.subject | HIV Antigens | |
dc.subject | HIV Infections | |
dc.subject | HIV-1 | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Virus Replication | |
dc.subject | Young Adult | |
dc.title | Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. | |
dc.type | Journal article | |
duke.contributor.orcid | Ferrari, G|0000-0001-7747-3349 | |
duke.contributor.orcid | Cunningham, CK|0000-0002-7725-3052 | |
duke.contributor.orcid | Crump, JA|0000-0002-4529-102X | |
duke.contributor.orcid | Tomaras, GD|0000-0001-8076-1931 | |
pubs.author-url | ||
pubs.begin-page | 6835 | |
pubs.end-page | 6846 | |
pubs.issue | 12 | |
pubs.organisational-group | Basic Science Departments | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Duke Human Vaccine Institute | |
pubs.organisational-group | Global Health Institute | |
pubs.organisational-group | Immunology | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Institutes and Provost's Academic Units | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Medicine, Duke Human Vaccine Institute | |
pubs.organisational-group | Medicine, Infectious Diseases | |
pubs.organisational-group | Molecular Genetics and Microbiology | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | Pediatrics | |
pubs.organisational-group | Pediatrics, Infectious Diseases | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Staff | |
pubs.organisational-group | Surgery | |
pubs.organisational-group | Surgery, Surgical Sciences | |
pubs.organisational-group | University Institutes and Centers | |
pubs.publication-status | Published | |
pubs.volume | 86 |
Files
Original bundle
- Name:
- JVirol_InitialHIVAgSpecificCD8.pdf
- Size:
- 1.89 MB
- Format:
- Adobe Portable Document Format